Related Experiment Video

Updated: May 22, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Long-term ongoing coagulopathy in premature infants with respiratory distress syndrome

Muammer Buyukinan1, Deniz Yilmaz, Mehmet Yalaz

  • 11Division of Neonatology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|May 5, 2012
PubMed

Insights

Infants with respiratory distress syndrome (RDS) show long-term coagulation issues. Their antithrombin activity remained low, indicating persistent coagulopathy over six months.

Area of Science:

  • Neonatalogy
  • Hematology
  • Pediatric Critical Care

Background:

  • The acute phase of respiratory distress syndrome (RDS) involves an activated intravascular coagulation system.
  • Long-term evaluation of coagulation in premature infants with RDS is lacking.

Purpose of the Study:

  • To assess coagulation system activity in premature infants with RDS over a six-month period.
  • To compare coagulation parameters in infants with RDS to healthy premature infants (HPIs), healthy mature infants (HMIs), and laboratory controls.

Main Methods:

  • Longitudinal study over six months involving cord and venous blood sampling at birth, one month, and six months.
  • Measurement of Protein C (PC), free protein S (f-PS), antithrombin (AT) activities, thrombin-antithrombin (TAT) complex, prothrombin fragment 1 + 2 (PF1 + 2), and fibrinogen levels.
  • Comparison of coagulation markers between RDS infants, HPIs, HMIs, and controls.

Main Results:

  • PC, f-PS, d-dimer, and fibrinogen levels were similar between HPI and RDS groups throughout the study.
  • Anticoagulant proteins increased in HMIs and HPIs within six months.
  • Infants with RDS exhibited persistently lower AT activity and significantly higher TAT and PF1 + 2 levels at one and six months.

Conclusions:

  • Infants with RDS experience long-term consumption coagulopathy.
  • Persistent alterations in coagulation markers suggest ongoing thrombotic risk in infants with RDS.
  • Further research is warranted to explore therapeutic interventions for long-term coagulation disturbances in RDS.

Keywords:
blood coagulation factorsconsumption coagulopathynewbornrespiratory distress syndrome

More Related Videos

A Swine Model of Neonatal Asphyxia10:36

A Swine Model of Neonatal Asphyxia

Published on: October 11, 2011

Transcutaneous Microcirculatory Imaging in Preterm Neonates06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Endoscopic Studies II: Thoracocentesis01:26

Endoscopic Studies II: Thoracocentesis

Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...